Dafeng Port Heshun Tech Stock (OTC: DPHTF)

Latest news for Dafeng Port Heshun Tech (OTC:DPHTF) Stock

Dafeng Port Heshun Technology Co Ltd is engaged in the trading and import and export businesses of electronic products, petrochemical products, and other products. The company operates through Integrated logistics handling services, Petrochemical products storage business and trading business.

DAFENG PORT HESHUN TECH by DAFENG PORT HESHUN TECHNOLOGY CO LTD.

Dafeng Port Heshun Technology Co Ltd

Truist Securities analyst Srikripa Devarakonda maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and lowers the price target from $215 to $211.

News

Price Target

Analyst Ratings

ABBV

Truist Securities Maintains Buy on AbbVie, Lowers Price Target to $211

Earnings

Guidance

Health Care

General

ANGO

AngioDynamics Expects 2025 Adjusted EPS Loss Of $0.34 to $0.38 Compared To Prior Guidance Of $0.38-$0.42 And Consensus Of $0.40

Truist Securities analyst Robyn Karnauskas downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowers the price target from $130 to $110.

Downgrades

Truist Securities Downgrades Merck & Co to Hold, Lowers Price Target to $110

Needham analyst Mike Matson maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and maintains $7.25 price target.

PSNL

Needham Maintains Buy on Personalis, Maintains $7.25 Price Target

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy rating and announces Price Target of $4.

Initiation

NKTR

B. Riley Securities Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $4

<ul>
<li>The Company now expects Med Tech net sales to grow in the range of 12% to 15%, an increase from 10% to 12%</li>
<li>The Company now expects Med Device net sales to be flat, a decrease from 1% to 3%</li>
<li>The Company continues to expect Gross margin to be approximately 52% to 53%</li>
<li>The Company now expects Adjusted EBITDA in the range of $1.0 to $3.0 million, an increase from the previous guidance of a loss of $2.5 million to $0. The updated guidance compares to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024</li>
</ul>

AngioDynamics Continues To Expect 2025 Net Sales Of $282M-$288M, Representing Growth Of Between 4.2%–6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $283.86M

Air Lease Announced That It Delivered 18 New Aircraft From ALC's Orderbook And Sold 14 Aircraft To Third-party Buyers In The Q4 FY24

As of Jan. 8, 2025, two stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Lesaka Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSAK#NASDAQ">LSAK</a>)</h3>
<ul>
<li>Lesaka Technologies will release second quarter 2025 results after the closing bell on Feb. 5. The company's stock surged around 13% over the past six months and has a <a href="https://www.benzinga.com/quote/LSAK">52-week high of $5.60</a>.</li>
<li>RSI Value: 71.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LSAK Price Action: Shares of Lesaka Technologies jumped 2.3% to close at $5.27 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Central Plains Bancshares Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPBI#NASDAQ">CPBI</a>)</h3>
<ul>
<li>On Oct. 28, Central Plains Bancshares adopted repurchase program of up to 200,000 shares of its common stock. The company's stock gained around 4% over the past month and <a href="https://www.benzinga.com/quote/CPBI">has a 52-week high</a> of $15.46.</li>
<li>RSI Value: 74.3</li>
<li>CPBI Price Action: Shares of Central Plains Bancshares gained 1.4% to close at $15.00 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li>B<a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">ank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CPBI

LSAK

Top 2 Financial Stocks That May Fall Off A Cliff In January

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $22 price target.

STOK

Needham Maintains Buy on Stoke Therapeutics, Maintains $22 Price Target

Morgan Stanley analyst Alex Poon upgrades NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) from Equal-Weight to Overweight and raises the price target from $90 to $108.

Upgrades

NTES

Morgan Stanley Upgrades NetEase to Overweight, Raises Price Target to $108

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">Second Quarter Fiscal 2025 Financial Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">ADS Growth (YoY)</td>
<td colspan="1" rowspan="1">(5.0)% - (3.0)%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Margin1</td>
<td colspan="1" rowspan="1">6.5% - 7.5%</td>
</tr>
</tbody>
</table>
</figure>

MSC Industrial Projects Q2 Fiscal 2025 ADS Decline Of 3%-5% And Operating Margin Of 6.5%-7.5%

<a href="https://www.wsj.com/articles/amd-invests-in-drug-discovery-company-absci-in-push-to-sell-ai-chips-ba9ef2b1?mod=Searchresults_pos1&amp;page=1" title="https://www.wsj.com/articles/amd-invests-in-drug-discovery-company-absci-in-push-to-sell-ai-chips-ba9ef2b1?mod=Searchresults_pos1&amp;page=1">https://www.wsj.com/articles/amd-invests-in-drug-discovery-company-absci-in-push-to-sell-ai-chips-ba9ef2b1?mod=Searchresults_pos1&amp;page=1</a>

ABSI

The Wall Street Journal Reported Advanced Micro Devices Invests $20M n Drug-Discovery Startup Absci

On Monday, Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) announced a major rebranding of its personal computers, aiming to boost sales by adopting a simplified naming strategy similar to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
What Happened: The company has decided to retire long-standing product names like &#8220;XPS&#8221; and &#8220;Inspiron&#8221; in favor of a streamlined approach centered around the Dell name.
The rebranding is part of Dell&#8217;s strategy to make its products more appealing and less confusing for consumers. The new lineup will feature three tiers: Dell, Dell Pro, and Dell Pro Max, echoing Apple&#8217;s naming conventions.
See Also: <a href="https://www.benzinga.com/tech/25/01/42838231/jensen-huang-unveils-3000-personal-ai-supercomputer-the-size-of-a-small-book-it-runs-the-entire-nvidia-ai-stack">Jensen Huang Unveils $3000 ‘Personal AI Supercomputer' The Size Of A Small Book: ‘It Runs The Entire Nvidia AI Stack'</a>
The rebranding is also part of a broader effort to encourage PC upgrades, with AI-optimized systems and the end of support for Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Windows 10 as potential catalysts.
Notably, Dell&#8217;s gaming brand, Alienware, will not be affected by the rebranding. The new Dell-branded devices will incorporate neural processing units to improve AI capabilities.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: In November 2024, Dell announced earnings of $2.15 per share for the third quarter, surpassing the analyst consensus estimate of $2.05.
However, the <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">company's quarterly revenue</a> totaled $24.37 billion, falling short of the expected $24.65 billion, though it represented a growth from the $22.25 billion recorded during the same quarter last year.
In the third quarter of 2024, Dell&#8217;s share of global PC shipments dropped to 15.7%, down from 16.7% in the previous quarter. The company remains the third-largest PC vendor worldwide, trailing behind Lenovo and HP, according to Statista.
Price Action: Dell's stock fell by 2.72% on Tuesday, ending the day at $121.27. However, the stock bounced back in Wednesday's pre-market session, increasing by 1.3% to $122.85, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/01/42827345/nvidia-soars-amd-stalls-ai-race-heats-up-at-ces-2025">Nvidia Soars, AMD Stalls: AI Race Heats Up At CES 2025</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

AAPL

DELL

MSFT

Dell Simplifies PC Lineup With Apple-Like Branding: XPS, Inspiron Brands Are Gone For Good

Goldman Sachs analyst Alex Scott upgrades Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Sell to Buy and announces $278 price target.

Goldman Sachs Upgrades Travelers Companies to Buy, Announces $278 Price Target

MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.73 by 17.81 percent. This is a 31.2 percent decrease over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $928.500 million which beat the analyst consensus estimate of $904.604 million by 2.64 percent. This is a 2.67 percent decrease over sales of $953.969 million the same period last year.

Earnings Beats

MSC Industrial Direct Co Q1 2025 Adj. EPS $0.86 Beats $0.73 Estimate, Sales $928.500M Beat $904.604M Estimate

Needham analyst Gil Blum maintains Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) with a Buy and lowers the price target from $10 to $8.

GBIO

Needham Maintains Buy on Generation Bio, Lowers Price Target to $8

GTLS

Chart Industries Announce Its Signing Of A Global Master Goods And Services Agreement With ExxonMobil

Goldman Sachs analyst Robert Cox downgrades Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) from Neutral to Sell and lowers the price target from $21 to $16.

FIHL

Goldman Sachs Downgrades Fidelis Insurance Hldgs to Sell, Lowers Price Target to $16

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. The company reported quarterly sales of $73.02 million which beat the analyst consensus estimate of $70.93 million by 2.93 percent. This is a 9.17 percent increase over sales of $66.88 million the same period last year.

AngioDynamics Q2 2025 Adj EPS $(0.04) Beats $(0.11) Estimate, Sales $73.02M Beat $70.93M Estimate

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $13 price target.

Comments

Dafeng Port Heshun Tech

News

Latest news for Dafeng Port Heshun Tech (OTC:DPHTF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga